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 Abstract  
Aerobic vaginitis (AV) is an endogenous opportunistic infection brought about by the 
disruption of the normal vaginal microbiota. Its early diagnosis and treatment during 
pregnancy may reduce the risk of negative pregnancy outcomes. The aim of this review 
was to report on the aerobic bacteria most prevalent in AV and to provide evidence of the 
threat of untreated AV on pregnancy outcomes. More than 300 papers on preterm 
delivery were extracted from several research domains and filtered to include only AV-
associated bacteria such as Staphylococcus aureus, Enterococcus faecalis, Escherichia 
coli and Group B streptococci and their association with adverse pregnancy outcomes. 
Due to the diverse sample groups, study techniques and outcomes, a meta-analysis was 
not conducted. The review revealed that the association of AV with adverse pregnancy 
outcomes has not been as widely researched as bacterial vaginosis (BV) and needs further 
investigation. Furthermore, the frequent misdiagnosis of AV coupled with the emerging 
antimicrobial resistance associated with bacteria implicated in AV and neonatal 
nosocomial infections pose a problem for prophylaxis and treatment to reduce the risk of 
maternal and neonatal morbidity and mortality. 
 
Introduction 
Despite the advances in prenatal care and increased public awareness, adverse 
pregnancy outcomes still present a major public health problem worldwide. The human 
vagina is colonised by a very diverse microbiota which plays   a   protective    role    in    
health    but when   disrupted, can impact   negatively on   the reproductive health of 
women, particularly during pregnancy1. The increasing incidence of preterm delivery2 
and other complications of pregnancy such as intra-amniotic infection3 and 
chorioamnionitis4 not only affect the mother, but her foetus as well2. Although 
vulvovaginal conditions  such  as  Candida  vaginitis,  bacterial vaginosis and 
trichomoniasis are commonly identified  and  diagnosed,  less  is  known  about aerobic 
vaginitis (AV). AV has been described as a disruption of the normal vaginal microbiota 
with a reduction in hydrogen peroxide-producing lactobacilli in a mainly facultatively 
anaerobic microbiota, accompanied by an increased vaginal pH, signs of inflammation 
with leukocyte infiltration5-9. AV differs distinctly from bacterial vaginosis (BV) in its 
clinical features and host response with BV being a condition brought about by an 
imbalance and shift of the normal vaginal flora in favour of anaerobic bacteria with no 
signs of inflammation6. 
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Although the association of BV with pregnancy outcomes has been extensively studied, 
not much has been published pertaining to the epidemiology and aetiology of AV and its 
influence on pregnancy outcomes. Little is known about treatment success in reducing 
adverse pregnancy outcomes in mothers with AV infection although it is suspected that 
treatment failure may be largely attributed to the emerging drug resistance of AV-
associated bacteria. 
 
The aim of this review is to report on the frequency of AV-associated bacteria in 
pregnancy and to provide evidence of the influence of untreated AV infection on 
pregnancy  outcomes and neonatal morbidity. 
 
Methods 
Using PubMed, WSI, Research Gate, Google Scholar and World of Science, > 300 
papers were screened using the keywords ―preterm, vaginal endogenous infections, 
maternal and neonatal morbidity and mortality‖. For this review, only papers published 
between the years 2000 and 2016 were included which described bacteria commonly 
associated with AV (Escherichia coli, Group B streptococci, Staphylococcus aureus and 
Enterococcus faecalis) and known to pose a risk for adverse pregnancy outcomes and 
subsequent neonatal infection. Papers published before the year 2000 were excluded on 
the basis that AV was an observed but uncategorized condition in 2000 with the 
diagnostic criteria for AV only formally proposed in 2002 by Donders et al6. Excluded 
from the search were adverse maternal and neonatal outcomes due to exogenous  
infections and  other  endogenous  infections  such  as  BV. Because of the diverse 
sample groups, techniques and outcomes, a meta-analysis was not conducted. 
 
Diagnosis and treatment of AV 
The appropriate diagnosis and distinction between AV and BV is crucial to their 
treatment and may reduce preterm birth11. The diagnosis of AV is based on wet mount 
microscopy, showing vaginal smears deficient in lactobacilli, with the presence of cocci 
or coarse bacilli, parabasal epithelial cells, and toxic leucocytes9,12. Similar to the Nugent 
scoring system used for grading BV, a composite AV score is obtained by grading each of 
the above as normal or slight (0), moderate (1) or severe (2)5,9. The number of points 
establishes the composite AV score, with the maximum score being 105. Furthermore, 
lactobacillary grades (LBG) may range from I (increased lactobacilli, decreased cocci), 
through II (reduced lactobacilli with a mixed background microbiota) and III (mixed 
bacteria in the absence of lactobacilli)5,13. Parabasal cells are considered a sign of severe 
epithelial inflammation encountered only in moderate or severe forms of AV such as 
in desquamative inflammatory vaginitis12. This, inflammatory reaction along with the 
thinned vaginal mucosa are thought to contribute to the symptoms of AV5. 
 
Although widely accepted as efficient in diagnosing AV, the above method is time- 
consuming, only employs a microscopic examination and is often adapted according to 
available resources14. A commercial kit developed in China (Beijing ZhongSheng JinYu 
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Diagnosis Technology Co., LTD, Beijing, China) demonstrated an ability to diagnose 
AV with accuracy and sensitivity of 90% and has been proposed as a rapid alternative 
for the diagnosis of AV in China15. AV is diagnosed if the diagnostic strip tests indicate a 
colour change to measure hydrogen peroxide concentration (reflecting the status of 
lactobacilli), leucocyte esterase activity (presence of inflammation), β-glucuronidase 
activity (the presence of E. coli and GBS) and coagulase (detecting S. aureus) thereby 
eliminating the use of microscopy in the often overcrowded outpatient clinics. 
 
Because of differences in their microbial aetiology,  the  prophylaxis  and  treatment  of  
AV and BV differ. Metronidazole is commonly used for the treatment of BV12 and 
because AV does not respond well to metronidazole, clindamycin is considered to be a 
better choice for treating pregnant women with an unconfirmed diagnosis of abnormal 
vaginal microbiota because it is able to eradicate both AV and BV-associated bacteria16. 
Topical application of kanamycin has also been reported17 as well as the use of 
probiotics18. Conventional treatment for AV consists of a course of broad-spectrum 
antibiotics that target anaerobic and aerobic bacteria such as the aminoglycoside, 
kanamycin5,19 and the quinolone, moxifloxacin19, both of which are proven to be 
effective. 
 
Maternal and neonatal risk posed by AV infection during pregnancy 
The presence of an abnormality in the vaginal microbiota in early pregnancy is 
considered to be one of the most significant risk factors for preterm delivery, preterm 
pre-labor rupture of membranes (PPROM) and low birth weight5,11. The inability to 
diagnose subclinical ascending uterine infection may result in foetal infection with a 
neonatal mortality rate of 25%-90% due to congenital neonatal sepsis10. 
 
During pregnancy the vaginal biofilm, conditioned by high estrogen levels, has a good 
supply of glycogen and an elevated proportion of lactobacilli, reported to constitute > 
90% of the microorganisms present in the vagina during childbearing age19. The  
increased concentrations of circulating estrogens, accompanied by increased numbers of 
parabasal cells yields infrequent reports of AV in pregnancy5. However, there is a clear 
indication that, even when  asymptomatic, AV may represent a risk factor for preterm 
delivery20,21 and other complications of pregnancy such as ascending chorioamnionitis 
and PROMS5,22,23 
 
In AV, the concentrations of pro- inflammatory cytokines, interleukin – 1b (IL-1b), 
interleukin – 6 (IL-6) and interleukin – 8 (IL-8), are inversely proportional to LBG5, 
and because these cytokines have been associated with adverse pregnancy outcomes, 
patients with AV may similarly   be   at   increased   risk   of   delivering preterm5,13.   IL-
1b   demonstrates   an   eight   fold increase in AV compared to bacterial vaginosis (BV), 
while IL-6 increases fivefold in those diagnosed with AV7,13 and is a well-recognized 
marker for bacterial amnionitis and imminent term and preterm delivery13. IL-8 is 
considered to play a significant role in neonatal infections with elevated serum 
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concentrations of IL-8 observed within the first 24 hours in severe cases of necrotizing 
enterocolitis (NEC)24. NEC is described as the most serious gastrointestinal disorder 
in newborn infants with an incidence of 10 – 15% in those with very low birth 
weight25. Thus, the host response to AV contributes significantly to both maternal and 
neonatal morbidity. 
 
At birth, an infant‘s gastrointestinal tract is sterile. However it rapidly becomes colonized 
with organisms from the mother and the local environment, with enterococci and 
members of the family Enterobacteriaceae being the predominant organisms found in 
the stools during the first days of life in full-term infants26,27. In the preterm neonates, 
especially those with a very low birth weight, other factors such as the 
underdeveloped crucial functions, the mode and environment of delivery, as well as 
feeding and drug therapy regimens may influence the biodiversity of the intestinal flora 
and increase the risk of gastrointestinal disease such as NEC27. 
 
Early onset neonatal sepsis (EOS) occurs within the first few days of life and remains 
an uncommon but significant cause of morbidity and mortality among very low birth 
weight (VLBW) infants28,29, while late onset neonatal sepsis (LOS) occurs between 4-7 
days of life and is associated with the morbidity and mortality of hospitalized neonates 
worldwide due to invasive interventions, prolonged ventilation and prolonged stay in 
neonatal intensive care units as a consequence of prematurity and VLBW30. 
 
Organisms commonly implicated in AV and associated with negative pregnancy and 
neonatal outcomes include Escherichia coli, Group B streptococci (also known as 
Streptococcus agalactiae and referred to as GBS for the remainder of this review), 
Enterococcus faecalis and Staphylococcus aureus18,31,32,  and when acquired during the 
perinatal period, may be associated with a high neonatal mortality due to septicemia, 
meningitis or pneumonia32,33. 
 
Escherichia coli (E. coli) 
E.coli accounts for 80 to 90% of AV infections in pregnant women31 and is frequently 
isolated as the sole organism5. E. coli has also been  more frequently reported in women 
who deliver preterm than those delivering full term34,35. The physiologic changes along 
with reduced immunological status during pregnancy are believed to predispose women 
to urinary tract infections (UTI) with E. coli being the most commonly associated 
pathogen. Specific virulence determinants in uropathogenic strains of E. coli are 
associated with invasive infection and pyelonephritis in pregnancy by facilitating their 
adherence to uroepithelial cells, thereby preventing bacteria from urinary lavage and 
allowing for multiplication and tissue invasion31. 
 
Some studies have reported an emerging trend of E. coli predominating in early 
neonatal sepsis following prophylaxis for GBS colonization during pregnancy36-41. Even 
though the role of E. coli in vaginitis is particularly controversial, it is known to alter 
the micro-environment19 and remains one of the most common causes of neonatal 
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sepsis, often being recovered from placental tissues in chorioamnionitis5. Neonates born 
preterm are more likely to develop neonatal sepsis and meningitis caused by E. coli 
compared with neonates born at term28,29. 
 
A study by Bizzaro et al.42 revealed that there were significant increases in both EOS 
and LOS which could be attributed to E. coli. A significant increase in ampicillin-
resistant E. coli was reported in very low birth weight infants with E. coli EOS, while in 
E. coli LOS, no significant change in antimicrobial susceptibility was reported42. 
 
Group B Streptococci (GBS) 
GBS exists as normal microbiota in the female genital tract and anal areas of healthy 
adults43-46, with an estimated one out of three women being a carrier of GBS. The 
gastrointestinal tract serves as the natural reservoir for GBS and is expected to be the 
source of vaginal colonization23,43. 
 
Pregnant women who are colonized with GBS might develop infections of the urinary 
tract, bacteremia, chorioamnionitis, and postpartum endometritis23,47,48, thus increasing 
the risk of PTD, PPROM and perinatal transmission49-51, resulting in neonatal sepsis 
and meningitis45,52,53. A prevalence of 7 - 25% GBS colonization in AV has been 
reported in women between 35 and 37 weeks of gestation54, with intrauterine infection 
associated with the ability of GBS to ascend from the lower genital tract and colonize the 
upper genital tract54-56. In the newborn, GBS infection may be congenital or acquired22, 
57 and remains the foremost cause of neonatal mortality  and morbidity in the world 
despite a recent decline in occurrence48,52,58,59. 
 
GBS early-onset disease (EOD) occurs at the age of 0-6 days and has been associated 
with the presence of GBS in the vagina of the mother with transmission thought to 
take place vertically through aspiration of infected amniotic fluid or passage through the 
birth canal60-62, while late- onset disease (LOD), occurs at age between 7 and 90 
days48,62,63 with the source of infection attributed to community or nosocomial 
acquisition62. However, there is evidence that in several infants with LOD, the GBS 
causing the infection share identical serotypes as the GBS isolated from their mothers, 
suggesting a maternal source48,62. 
 
Intrapartum colonization is strongly associated with approximately 4% of neonatal 
fatalities and serious morbidities including sepsis, pneumonia, meningitis, illness and 
death in infants, as well as long-term disabilities such as loss of hearing, impaired 
vision, developmental problems, cerebral palsy, osteomyelitis and septic arthritis22,58. 
 
Staphylococcus aureus (S. aureus) 
The rate of vaginal carriage of S. aureus has been reported to be 4% – 22% of the vaginal 
microbiota of pregnant women64,65, with the presence of lactobacilli known to reduce 
S. aureus virulence8. The risk factors for S. aureus colonization in pregnancy and the 
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association between maternal colonization and infant infections are not very well 
defined64. 
 
S. aureus accounts for > 90 % of late- onset sepsis in neonates. Late-onset sepsis is noted 
to be four times higher in very low birth weight (VLBW) infants66. Imperative factors 
that are considered to increase the risk for neonates due to S. aureus colonization 
include breastfeeding, number of household members, prematurity, low birth weight 
and the duration of antibiotic or ventilator days67-69. 
 
Traditional antibiotic therapy, even though highly effective, has led to the emergence of 
antibiotic-resistant strains, such as methicillin resistant S. aureus (MRSA)70. 
Community- acquired MRSA infections have been reported to occur in neonates and 
pregnant women or postpartum women, as a result of vaginal colonization of S. aureus 
during pregnancy70, with a prevalence of 0.5% - 10% and in some areas, higher rates 
of colonization have been reported64,68,71. The factors that contribute to S. aureus 
rectovaginal colonization in pregnant women are not well understood, but it is 
believed to include black race64,72. MRSA is noted as a significant pathogen in neonatal 
intensive care units67, with one study reporting 1.8% of neonates colonized with 
MRSA and 16 of 50 (32%) of these colonized neonates developing MRSA infection69. 
 
Enterococcus faecalis 
Lancefield group D streptococci include the enterococci now classified in a separate 
genus from other streptococci and non-enterococcal group D streptococci. Group D 
enterococci and non-enterococci are part of the genital tract, but are a common 
cause of urinary tract infections, subacute bacterial endocarditis, abdominal abscesses, 
and wound infections73,74. The predominance of asymptomatic genital tract infection 
in pregnant women has been reported in the literature75, with enterococci causing life 
threatening infections in preterm infants and other immuno-compromised patients73. 
 
The enterococcal species which are considered to be significant pathogens for humans 
are E. faecalis and E. faecium. These organisms are likely to affect patients who are 
elderly or whose  normal  microbiota  has  been  altered  by antibiotic treatment73. 
Furthermore, in neonates, E. faecalis is associated with 6% mortality rate in early onset 
septicaemia (EOS) which increases to 15% in late-onset (LOS) infections, whilst in 
general it is implicated in 7% to 50% of fatal cases74. 
 
Enterococci have previously been reported to be harmless inhabitants of the 
gastrointestinal tract flora initially, and are included among the main causes of health 
care–associated infections76, being recorded as the second most common cause of 
nosocomial urinary tract infections77. E. faecalis is considered to increase tst expression 
leading to increased production of toxic shock syndrome toxin-1 (TSST-1) thus 
increasing the virulence of S. aureus. Enterococci are believed to be difficult to treat 
because of their intrinsic resistance to antibiotics including beta – lactams and 
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aminoglycosides which are frequently used to treat infections due to Gram-positive 
cocci74,78. Resistance to trimethoprim, gentamycin and vancomycin have also been 
reported79,80. 
 
An association was found between increased enterococcal colonization and 
prematurity73, with preterm birth neonates who carry E. faecalis being more likely to be 
suffering from NEC than neonates born at term24, 25. The presence of E. faecalis in 
the amniotic fluid considerably increases the risk of histological inflammation of the 
placenta (OR 10.7, 95% CI 1.27–89.9) and also increases the risk for 
bronchopulmonary dysplasia (BPD) and NEC81. 
 
E. faecalis is described as one of the first colonizers that could suppress the 
inflammatory responses and also shape the immune system of neonates24. In the 
neonates, the intestines are likely to undergo acute inflammation when exposed to 
Gram-negative bacteria24. The presence of E. faecalis is believed to help the intestines 
maintain the immune balance in response to such challenges24. However, the 
therapeutic effects of E. faecalis must be examined thoroughly, especially as E. faecalis is 
a recognized opportunistic pathogen in hospital infections24,78. 
 
Conclusion 
Preterm birth is a critical priority in healthcare throughout the world because of 
medical, social, and  economic  reasons.  Maintaining  a  healthy vaginal biofilm during 
pregnancy is vital to the control of opportunistic infection which may result in poor 
pregnancy outcomes. Optimal treatment includes antibiotics that have little consequence 
on the normal beneficial microbiota such as Lactobacillus species, while eradicating E. 
coli, GBS, S. aureus, and E. faecalis all of which have been implicated in the aetiology 
of AV19,82,26. The administration of probiotic lactobacilli employed in recent studies 
restores the disrupted microflora of the vagina and offers a safer alternative to the 
prolonged prophylactic use of antibiotics which may present with side effects83,84. 
 
As with most endogenous infections, species prevalence differs among the different 
geographical regions with some reporting S. aureus as the most prevalent85,19,9, followed 
by E. coli85,86 Enterococcus85,87 and GBS86. Others report E. coli followed by E. 
faecalis88,89, GBS and Enterobacteriaceae90.    There    is    currently    no standardized 
treatment for AV infected mothers to reduce the rate of adverse pregnancy outcomes18, 
although treatment during the second trimester of pregnancy has been advocated10. 
 
The effects of screening and treatment for abnormal vaginal microbiota in order to 
reduce preterm delivery (PTD) remain controversial21 with low prevalence of AV 
reported in some studies11,91 and others showing a very high prevalence92,93. 
Interventions to prevent pre-term birth have been largely ineffective1,2 and may be 
attributed to both the increasing antimicrobial resistance amongst opportunistic 
pathogens which complicates adequate administration  of prophylaxis and treatment as 
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well as the often misdiagnosis of AV as BV, thus leading to treatment failures and 
thereby contributing to and increasing the risk of maternal and neonatal morbidity. 
 
The paucity of studies relative to AV and pregnancy outcomes emphasizes the need for a 
better understanding of the epidemiology, aetiology and pathogenesis of AV in both 
pregnant and non-pregnant women particularly in Africa where AV has been poorly 
investigated and has often not been considered as a risk factor for poor pregnancy 
outcomes which may contribute to maternal and neonatal morbidity. 
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